Advertisement

Tumor Biology

, Volume 35, Issue 5, pp 4369–4375 | Cite as

Efficacy and safety of capecitabine as maintenance treatment after first-line chemotherapy using oxaliplatin and capecitabine in advanced gastric adenocarcinoma patients: a prospective observation

  • Miao-zhen Qiu
  • Xiao-li Wei
  • Dong-sheng Zhang
  • Ying Jin
  • Yi-xin Zhou
  • De-shen Wang
  • Chao Ren
  • Long Bai
  • Hui-yan Luo
  • Zhi-qiang Wang
  • Feng-hua Wang
  • Yu-hong Li
  • Da-jun Yang
  • Rui-hua Xu
Research Article

Abstract

The value of maintenance therapy after first-line chemotherapy has been verified in lung cancer and colorectal cancer, however, in gastric cancer, the role of maintenance therapy is still waiting for an answer. The aim of this study is to evaluate the efficacy and safety of capecitabine as maintenance treatment after first-line chemotherapy in advanced gastric adenocarcinoma patients in China. Specimens of patients with advanced gastric adenocarcinoma who were given 6 cycles of oxaliplatin and capecitabine (Xelox for short) as first-line chemotherapy, without disease progression and with grade 2 or higher neuropathy, were collected for analysis. Among them, 64 patients received capecitabine as maintenance (group A) and 222 patients without maintenance as group B. Survival analysis was performed with a Cox regression model. Grades 3–4 adverse events were uncommon; hematologic toxicity was infrequent (5 %) and consistently mild in the phase of maintenance treatment. The median progression-free survival (PFS) was 11.4 months [95 % confidence interval (CI), 10.2–12.6 months] for group A patients, while it was 7.1 months (95 % CI, 6.1–8.0 months) for patients in group B, P < 0.001. The multivariated analysis showed that the maintenance treatment was an independent prognostic factor in advanced gastric adenocarcinoma patients. The style of first-line treatment-maintenance therapy (Xelox-X) was active and feasible for advanced gastric adenocarcinoma patients who had suffered from grade 2 or higher level of neuropathy.

Keywords

Advanced gastric adenocarcinoma Capecitabine Maintenance therapy Prognostic factor 

Notes

Acknowledgments

We gratefully thank Professor Liu Qing in the epidemiology department for his suggestion in the statistical analysis. This study was supported by the following institutions: (1) National High Technology Research and Development Program of China (863 Program), China (no. 2012AA02A506); (2) Natural Science Foundation of China (no. 81372570); (3) National Natural Science Foundation of China (no. 81372570); (4) The Science and Technology Department of Guangdong Province, China (no. 2012B031800088); and (5) Medical Scientific Research Foundation of Guangdong Province, China (no. C2011019).

Conflicts of interest

None

References

  1. 1.
    Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;10:2137–50.CrossRefGoogle Scholar
  2. 2.
    Moore MA, Eser S, Igisinov N, Igisinov S, Mohagheghi MA, Mousavi-Jarrahi A, et al. Cancer epidemiology and control in North-Western and Central Asia–past, present and future. Asian Pac J Cancer Prev. 2010;11:17–32.PubMedGoogle Scholar
  3. 3.
    Cullinan SA, Moertel CG, Fleming TR, Rubin JR, Krook JE, Everson LK, et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA. 1985;253:2061–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358:36–46.CrossRefPubMedGoogle Scholar
  5. 5.
    Quek R, Lim WT, Foo KF, Koo WH, A-Manaf A, Toh HC. Capecitabine and oxaliplatin (XELOX) is safe and effective in patients with advanced gastric cancer. Acta Oncol. 2007;46:1032–4.CrossRefPubMedGoogle Scholar
  6. 6.
    Park YH, Lee JL, Ryoo BY, Ryu MH, Yang SH, Kim BS, et al. Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer. Cancer Chemo Pharmacol. 2008;61:623–9.CrossRefGoogle Scholar
  7. 7.
    Park YH, Kim BS, Ryoo BY, Yang SH. A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer. Br J Cancer. 2006;94:959–63.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Chibaudel B, Maindrault-Goebel F, Lledo G, Mineur L, André T, Bennamoun M, et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol. 2009;27:5727–33.CrossRefPubMedGoogle Scholar
  9. 9.
    Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer. 1998;34:1274–81.CrossRefPubMedGoogle Scholar
  10. 10.
    Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2 positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. Lancet. 2010;376:687–97.CrossRefPubMedGoogle Scholar
  11. 11.
    Belani CP, Brodowicz T, Ciuleanu TE, Krzakowski M, Yang SH, Franke F, et al. Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study. Lancet Oncol. 2012;13:292–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Li YH, Luo HY, Wang FH, Wang ZQ, Qiu MZ, Shi YX, et al. Phase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer. J Cancer Res Clin Oncol. 2010;136:503–10.CrossRefPubMedGoogle Scholar
  13. 13.
    Belani CP, Barstis J, Perry MC, La Rocca RV, Nattam SR, Rinaldi D, et al. Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol. 2003;21:2933–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Brodowicz T, Krzakowski M, Zwitter M, Tzekova V, Ramlau R, Ghilezan N, et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer. 2006;52:155–63.CrossRefPubMedGoogle Scholar
  15. 15.
    Novello S, Bruzzi P, Barone C, Buosi R, Masotti A, Michetti G, et al. Phase III study in stage IV non-small cell lung cancer patients treated with two courses of cisplatin/gemcitabine followed by a randomization to three additional courses of the same combination or gemcitabine alone. Ann Oncol. 2007;18:903–8.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Miao-zhen Qiu
    • 1
    • 2
  • Xiao-li Wei
    • 1
    • 2
  • Dong-sheng Zhang
    • 1
    • 2
  • Ying Jin
    • 1
    • 2
  • Yi-xin Zhou
    • 1
    • 2
  • De-shen Wang
    • 1
    • 2
  • Chao Ren
    • 1
    • 2
  • Long Bai
    • 1
    • 2
  • Hui-yan Luo
    • 1
    • 2
  • Zhi-qiang Wang
    • 1
    • 2
  • Feng-hua Wang
    • 1
    • 2
  • Yu-hong Li
    • 1
    • 2
  • Da-jun Yang
    • 2
    • 3
  • Rui-hua Xu
    • 1
  1. 1.Department of Medical OncologySun Yat-Sen University Cancer CenterGuangzhouChina
  2. 2.State Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer MedicineGuangzhouChina
  3. 3.Department of Experimental ResearchSun Yat-Sen University Cancer CenterGuangzhouChina

Personalised recommendations